KALA BIO, Inc. — Form SCHEDULE 13D/A
Filed July 2, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
▼ Likely negative
significance 52/100
What the filing says
David E. Lazar sold 115,737 shares of common stock between May 4 and June 29, 2026, at prices ranging from $2.18 to $5.61 per share (adjusted for 1-for-50 reverse split on May 8, 2026). Total proceeds approximately $252K. Lazar's filing reflects material insider selling activity amid the company's reverse stock split.
Why this rating
Substantial insider selling (6% of market cap proceeds) signals weak confidence; reverse split + stock price decline to $2.18 are distress indicators for micro-cap.
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.